AU2005304486B2 - Deamidated interferon-beta - Google Patents

Deamidated interferon-beta Download PDF

Info

Publication number
AU2005304486B2
AU2005304486B2 AU2005304486A AU2005304486A AU2005304486B2 AU 2005304486 B2 AU2005304486 B2 AU 2005304486B2 AU 2005304486 A AU2005304486 A AU 2005304486A AU 2005304486 A AU2005304486 A AU 2005304486A AU 2005304486 B2 AU2005304486 B2 AU 2005304486B2
Authority
AU
Australia
Prior art keywords
ifn
deamidated
protein analog
composition
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005304486A
Other languages
English (en)
Other versions
AU2005304486A1 (en
Inventor
Kenji Furuya
Deborah Johnson-Jackson
Diana Tierra Ruscio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of AU2005304486A1 publication Critical patent/AU2005304486A1/en
Application granted granted Critical
Publication of AU2005304486B2 publication Critical patent/AU2005304486B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2005304486A 2004-11-10 2005-11-10 Deamidated interferon-beta Ceased AU2005304486B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62683704P 2004-11-10 2004-11-10
US60/626,837 2004-11-10
PCT/US2005/040758 WO2006053134A2 (en) 2004-11-10 2005-11-10 Deamidated interferon-beta

Publications (2)

Publication Number Publication Date
AU2005304486A1 AU2005304486A1 (en) 2006-05-18
AU2005304486B2 true AU2005304486B2 (en) 2011-08-11

Family

ID=36337216

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005304486A Ceased AU2005304486B2 (en) 2004-11-10 2005-11-10 Deamidated interferon-beta

Country Status (16)

Country Link
US (2) US7595040B2 (enExample)
EP (1) EP1809662B1 (enExample)
JP (1) JP4891250B2 (enExample)
KR (1) KR101330626B1 (enExample)
CN (1) CN101056890B (enExample)
AT (1) ATE415421T1 (enExample)
AU (1) AU2005304486B2 (enExample)
BR (1) BRPI0517697A (enExample)
CA (1) CA2587061C (enExample)
DE (1) DE602005011321D1 (enExample)
ES (1) ES2318575T3 (enExample)
MX (1) MX2007004990A (enExample)
PL (1) PL1809662T3 (enExample)
PT (1) PT1809662E (enExample)
RU (1) RU2404190C2 (enExample)
WO (1) WO2006053134A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
AU2007284964A1 (en) * 2006-08-08 2008-02-21 Novartis Ag Recombinant interferon-beta with enhanced biological activity
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
EP2207890A4 (en) * 2007-10-05 2010-12-15 Barofold Inc HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
ES2736503T3 (es) * 2014-04-04 2020-01-02 Ares Trading Sa Nuevos análogos de la proteína IFN beta
RU2739261C1 (ru) * 2019-12-31 2020-12-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ количественного определения антипролиферативной активности интерферона-бета человека

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
DE69729880T3 (de) 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
DK1017413T4 (da) * 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
JP2003508028A (ja) * 1999-07-28 2003-03-04 ジェネンテック・インコーポレーテッド 腫瘍治療のための組成物と方法
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
RU2216345C1 (ru) * 2002-03-21 2003-11-20 Закрытое Акционерное Общество "Биокад" Средство, обладающее иммуномодулирующим, противовирусным, противобактериальным, регенерирующим, репаративным, мембрано- и гепатопротекторным действием
KR100541850B1 (ko) 2003-03-31 2006-01-11 삼성정밀화학 주식회사 인간 인터페론-베타 변이체 및 그의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAWASAKI, H. et al. Biochem. Biophys. Res. Commun. (2003) Vol. 312, pages 1082-1086 *

Also Published As

Publication number Publication date
PT1809662E (pt) 2009-02-26
BRPI0517697A (pt) 2008-10-14
DE602005011321D1 (de) 2009-01-08
CA2587061C (en) 2011-08-16
JP4891250B2 (ja) 2012-03-07
RU2007121515A (ru) 2008-12-20
WO2006053134A2 (en) 2006-05-18
RU2404190C2 (ru) 2010-11-20
PL1809662T3 (pl) 2009-07-31
US20060120998A1 (en) 2006-06-08
US7595040B2 (en) 2009-09-29
ATE415421T1 (de) 2008-12-15
KR101330626B1 (ko) 2013-11-18
AU2005304486A1 (en) 2006-05-18
MX2007004990A (es) 2007-06-14
JP2008519769A (ja) 2008-06-12
CN101056890A (zh) 2007-10-17
CA2587061A1 (en) 2006-05-18
CN101056890B (zh) 2012-05-09
KR20070084559A (ko) 2007-08-24
ES2318575T3 (es) 2009-05-01
WO2006053134A3 (en) 2006-08-31
EP1809662A2 (en) 2007-07-25
EP1809662B1 (en) 2008-11-26
US20090263355A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
EP0412149B1 (en) Use of il-7 in providing medications for stimulation of platelet production
EP3713592A1 (en) Partial agonists of interleukin-2
KR20040052481A (ko) 재조합 단백질의 수득률을 증가시키는 방법
US20090263355A1 (en) Deamidated interferon-beta
MXPA03002045A (es) Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
CZ414191A3 (en) Human interleukin-4
JP2005046158A (ja) ナチュラルキラー刺激因子
EP0876152A1 (en) Novel administration of thrombopoietin
ES2310413T3 (es) Factores asociados con el factor de necrosis del tumor receptor de tipo 2 (tnf-r2).
KR20160052537A (ko) 조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
US6171824B1 (en) Hybrid cytokines
US20090311216A1 (en) Recombinant interferon-beta with enhanced biological activity
US20050148507A1 (en) Method for the production of an N-terminally modified chemotactic factor
STEBBING PROTEINS AS THERAPEUTICS
CA2256368A1 (en) An interleukin-5 antagonist
CA2524270A1 (en) Method for the production of an n-terminally modified chemotactic factor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired